In a report released today, Peter Lawson from Barclays assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report), with a price ...

Title:Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader Presenting author: Paula G. O’Connor, M.D., ...

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

Schrödinger's stock has fallen 64% since January 2023, driven by missed revenue and EPS targets. Read why I maintain my hold ...

"I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute ...